​Mpox virus (formerly known as monkeypox), a double-stranded DNA virus belonging to the genus Orthopoxvirus, represents a renewed public health challenge following recent global outbreaks and its designation as a Public Health Emergency of International Concern. Although it shares superficial similarities with other viral exanthems, it possesses precise clinical determinants and a distinct morphological blueprint. These features enable the experienced clinician to formulate an accurate differential diagnosis, particularly when managing populations highly vulnerable to complications, such as pregnant individuals. ​1. Morphological Blueprint and Clinical Diagnosis ​The primary cornerstone of immediate clinical diagnosis relies on recognizing the distinct pattern of skin lesion evolution and distribution, which characteristically progress through synchronous stages: ​Synchronous Lesion Evolution (Monomorphic Rash): Unlike chickenpox (Varicella), which is characterized by a polymorphic rash appearing in successive crops at different evolutionary stages simultaneously, the Mpox rash develops synchronously and uniformly within any given anatomical region. Lesions progress collectively from macular stages to firm papules, then to clear vesicles, followed by deep pustules, and finally into dry crusts. ​Central Umbilication: Mpox pustules are typically deep-seated, firm to the touch, and develop a distinct central depression (umbilication) as the lesion begins to dry or necrose in the center. While this feature is shared with other infectious conditions like Molluscum Contagiosum, the lesions in Mpox are acutely painful and inflammatory. ​Lymphadenopathy: This feature serves as the most critical "clinical key" to differentiating Mpox from chickenpox. Mpox patients present with profound, painful lymphadenopathy (submandibular, cervical, and/or inguinal) that typically precedes or coincides with the onset of the cutaneous eruption. ​2. Laboratory Diagnosis and Investigational Strategies ​Despite strong clinical indicators, laboratory confirmation remains mandatory for lineage identification and establishing the therapeutic pathway: ​The Gold Standard: Polymerase Chain Reaction (PCR) testing is the most accurate and sensitive diagnostic investigation. ​Sampling Protocol: Specimens must be collected via vigorous swabbing of the lesion base, unroofing a vesicle or pustule, or collecting dry crusts. Clinically, it is highly recommended to obtain at least two swabs from anatomically distinct lesions to maximize diagnostic yield and rule out false-negative results. ​3. Mpox and Pregnancy: Maternal & Fetal Risks ​Mpox infection during pregnancy introduces compounded clinical challenges due to the immunological and physiological alterations inherent to gestation: ​Maternal Complications: Pregnant individuals face an elevated risk of severe disease manifestations, including secondary or viral pneumonia, severe cutaneous bacterial superinfections, and central nervous system involvement. ​Fetal Risks and Vertical Transmission: The virus is capable of transplacental crossing, leading to vertical transmission and Congenital Mpox. This significantly increases the incidence of: ​Spontaneous abortion (during the first and second trimesters). ​Intrauterine fetal demise (stillbirth). ​Severe preterm birth and associated prematurity complications. ​4. Clinical and Preventive Management During Pregnancy ​Managing an infected pregnant patient requires a conservative, meticulous medical approach that carefully weighs therapeutic benefits against potential risks: ​Supportive and Palliative Care: The clinical focus centers on maintaining fluid balance, utilizing pregnancy-safe antipyretics, and managing pruritus to prevent secondary bacterial infections, alongside close monitoring of maternal respiratory function. ​Antiviral Therapeutics: In severe or critical presentations, the administration of the antiviral agent Tecovirimat (TPOXX) may be considered. Although comprehensive safety and efficacy data in pregnancy are continually evolving, its deployment is clinically justified when the maternal clinical benefit outweighs the theoretical fetal risks. ​Labor and Delivery Management: The clinical decision regarding the mode of delivery depends heavily on the anatomical distribution of the lesions. If active genital or perianal lesions are present at the time of labor, a Cesarean section is indicated to prevent direct neonatal exposure to viral shedding and ulcerations during passage through the birth canal. ​Post-Exposure Prophylaxis (PEP): Upon confirmed exposure to a documented case, prompt administration of the third-generation, non-replicating smallpox/Mpox vaccine (MVA-BN, such as JYNNEOS) is recommended. This vaccine is scientifically preferred in pregnancy because it utilizes a non-replicating viral platform, making it completely safe for use during pregnancy without the risk of causing systemic or fetal infection, unlike older live vaccines. ​Conclusion ​Managing Mpox in modern clinical practice demands high precision in evaluating the morphological characteristics of the rash, correlating it with the medical history and lymphadenopathy. Early diagnosis, the deployment of PCR investigations, and the implementation of tailored preventive and therapeutic strategies for pregnant patients remain the cornerstones of minimizing morbidity and mortality associated with this virus.